Press Releases

March 21, 2018 Cernostics Raises $2.5 Million in Series A1 Financing, Led by Illumina Ventures

– TissueCypher® Barrett’s Esophagus Assay is First Precision Medicine Platform for Prevention of Esophageal Cancer – PITTSBURGH, Penn., March 21 2018 — Cernostics, a privately-held company focused on delivering next-generation cance... Read more

November 20, 2018 Cernostics Secures Additional Patents for Proprietary Barrett’s Esophagus Clinical Diagnostics

– US and EU patents for TissueCypher® cover methods for detecting risk of progression to esophageal cancer in Barrett’s esophagus patients – PITTSBURGH, Penn., November 20, 2018 — Cernostics, developer of next-generation cancer dia... Read more

May 8, 2019 Blinded Independent Validation Study of Tissue Systems Pathology Test in Determining Risk of Progression to Esophageal Cancer in Patients with Barrett’s Esophagus to be Presented at DDW 2019

PITTSBURGH, May 08, 2019 (GLOBE NEWSWIRE) — Cernostics, developer of next-generation cancer diagnostics and prognostics today announced that the results of an independent study validating the use of its TissueCypher Barrett’s Esophagus Assay ... Read more

July 1, 2019 Cernostics Announces Formation of Distinguished Medical Advisory Board Including Top Specialists in All Facets of Esophageal Disease

PITTSBURGH, Penn., July 1, 2019 — Cernostics, developer of next-generation cancer diagnostics and prognostics, today announced the formation of a distinguished medical advisory board (MAB) including key opinion leaders and world-renowned exp... Read more

October 22, 2019 TissueCypher® Further Validated to Accurately Risk Stratify Barrett’s Esophagus Patients with Non-Dysplastic or Low-Grade Dysplasia Diagnoses: Findings Shared at Two Major GI Conferences

Data presented at ACG, UEGW illustrates the 4th independent validation of TissueCypher performance for risk stratifying non-dysplastic Barrett’s esophagus (NDBE) patients; expands indication for testing low-grade dysplasia (LGD) PITTSBURGH, ... Read more

March 3, 2020 Cernostics Announces Groundbreaking Data Demonstrating TissueCypher® Performance for Predicting Risk of Progression to EAC in Patients with Non-Dysplastic BE

First-of-its-kind precision medicine test for esophageal pinch biopsies identifies high risk non-dysplastic BE patients that progress to EAC at rates higher than expert-confirmed LGD Pittsburgh, Penn., March 3, 2020 ̵ Cernostics, a lea... Read more

June 25, 2020 Cernostics Announces Blinded, Independent Validation of TissueCypher ® Performance for Predicting Risk of Progression to Esophageal Cancer in Patients with Non-Dysplastic BE

Study further validates TissueCypher® as the first and only precision medicine test proven to provide actionable data for predicting patient progression to high-grade dysplasia and esophageal adenocarcinoma Pittsburgh, Penn., June 25, 2020 – Cerno... Read more

News